Keith L Davis
Overview
Explore the profile of Keith L Davis including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
75
Citations
1233
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Passamonti F, Korgaonkar S, Parikh R, Chevli M, Yucel A, Rombi J, et al.
Future Oncol
. 2025 Jan;
21(5):579-591.
PMID: 39865562
Aim: Assess real-world fedratinib (FEDR) treatment patterns and clinical outcomes in patients with primary or secondary myelofibrosis following discontinuation of ruxolitinib (RUX). Patients & Methods: This study was a retrospective,...
2.
Weber J, Haque W, Markovic S, Salama A, Mehmi I, Sullivan R, et al.
Oncologist
. 2024 Nov;
PMID: 39560953
Background: In BRAF-mutated high-risk melanoma, targeted therapy (BRAF/MEK inhibitors) and checkpoint inhibitor (CPI) immunotherapy have durable benefits as first-line (1L) adjuvant therapy. Based on differing action mechanisms of BRAF/MEK inhibitors...
3.
Mody F, Goyal R, Ajmera M, Davis K, Amin A
Drugs Real World Outcomes
. 2024 Aug;
11(3):501-511.
PMID: 39088143
Background: In patients with heart failure with reduced ejection fraction (HFrEF), lower discharge heart rate (HR) is known to be associated with better outcomes. However, the effect of HR control...
4.
Furqan M, Karanth S, Goyal R, Cai B, Rombi J, Davis K, et al.
Future Oncol
. 2024 Apr;
20(22):1553-1563.
PMID: 38629593
To assess real-world clinical outcomes with standard therapies for advanced non-small-cell lung cancer (aNSCLC) with METexon14 skipping mutation (METex14). In an oncologists-led retrospective review of medical records, data were abstracted...
5.
Goyal R, Zhang J, Davis K, Sluga-OCallaghan M, Kaufman P
Breast Cancer Res Treat
. 2024 Feb;
205(1):201-210.
PMID: 38310616
Purpose: In 2010, the US Food and Drug Administration approved eribulin for the treatment of metastatic breast cancer (MBC). Since then, the treatment landscape has evolved with many new therapy...
6.
Goyal R, Zhang J, Davis K, Sluga-OCallaghan M, Kaufman P
Breast Cancer (Dove Med Press)
. 2023 Nov;
15:855-865.
PMID: 38020049
Introduction: Eribulin was approved by the FDA in 2010 for the treatment of metastatic breast cancer (MBC) in the United States (US). More recently, several immuno-oncology (IO) and antibody-drug conjugate...
7.
Esterberg E, Iyer S, Nagar S, Davis K, Tannir N
Clin Genitourin Cancer
. 2023 Nov;
22(2):115-125.e3.
PMID: 37914609
Background: Nearly 30% of new renal cell carcinoma (RCC) cases are diagnosed at an advanced or metastatic stage. Recent approvals of immunotherapies (IO) have significantly impacted patient care, but real-world...
8.
Wolf J, Souquet P, Goto K, Cortot A, Baik C, Heist R, et al.
Clin Lung Cancer
. 2023 Sep;
24(7):641-650.e2.
PMID: 37741716
Background: We evaluated the disease and patient characteristics, treatment, and MET testing patterns, predictive biomarkers and survival outcomes in patients with MET-dysregulated metastatic non-small-cell lung cancer (NSCLC) in a real-world...
9.
Davis K, Gutierrez B, Zyczynski T, Kaye J
J Health Econ Outcomes Res
. 2023 Sep;
2(2):119-130.
PMID: 37663582
Docetaxel has been a standard of care for castration-resistant prostate cancer (CRPC) in the United States since 2004, yet little has been reported on its patterns of use in routine...
10.
Paik P, Goyal R, Cai B, Price M, Davis K, Ansquer V, et al.
Future Oncol
. 2023 Feb;
19(3):217-228.
PMID: 36749292
To assess real-world clinical outcomes in patients with non-small-cell lung cancer with MET exon 14 skipping mutation and brain metastases (BM) who received capmatinib, a recently approved MET inhibitor, in...